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Combination effects of docetaxel (DOC) and doxorubicin (DOX) were investigated in prostate cancer cells (PC3 and DU145).
Combination indices (CIs) were determined using the unified theory in various concentrations and mixing ratios (synergy: CI <
0.9, additivity: 0.9 < CI < 1.1, and antagonism: CI > 1.1). DOC showed a biphasic cytotoxicity pattern with the half maximal
inhibitory concentration (IC50) at the picomolar range for PC3 (0.598 nM) and DU145 (0.469 nM), following 72 h drug exposure.
The IC50s of DOX were 908 nM and 343 nM for PC3 and DU145, respectively. Strong synergy was seen when PC3 was treated with
DOC at concentrations lower than its IC50 values (0.125∼0.5 nM) plus DOX (2∼8 times IC50). Equipotent drug combination
treatments (7 × 7) revealed that the DOC/DOX combination leads to high synergy and effective cell death only in a narrow
concentration range in DU145. This study provides a convenient method to predict multiple drug combination effects by the
estimated CI values as well as cell viability data. The proposed DOC/DOX mixing ratios can be used to design combination drug
cocktails or delivery systems to improve chemotherapy for cancer patients.
1. Introduction
Chemotherapy is widely used to treat cancer patients, but
most anticancer drugs show a narrow therapeutic window
[1]. Recent drug discovery and development studies are
focused on maximizing the therapeutic efficacy of potent
anticancer drugs at low dose levels [2]. Targeted drug
treatment and controlled drug delivery are techniques used
widely to achieve effective cancer treatment with reduced
toxicity. Targeted drug treatment is based on the rationale
to use therapeutic agents that act on molecular targets over
expressed in cancer cells, and thus to suppress cancer cell
growth or induce cell death selectively [3, 4]. Controlled
drug delivery is an approach to transport potent therapeutic
agents to disease lesions at the right dose level and time
[5]. In both approaches, cancer patients can benefit from
improved therapeutic efficacy.
We have been developing nanoparticulate drug delivery
systems that carry various therapeutic agents alone or in
combination to tumor tissues [6]. Despite promising
outcomes in preclinical and clinical studies, the therapeutic
efficacy of drug delivery systems appears to heavily rely on
the biological activity of drug payloads. Drug activity is
often determined by the concentrations at the site of action
and the delivery schedule. Drug mixing ratios also become
critical when multiple drugs are used in combination [7].
Multiple drugs can compete with each other for the same
transporter, molecular target, or have conflicting effects on
the cell cycle. Studies suggest that cancer cells are sensitive
to multiple drugs at a certain drug mixing ratio, and that
that optimal mixing ratio must be retained in tumor tissues
to achieve the maximal drug combination effect [8–12].
Therefore, it is critical to identify the optimal combination
settings and study the cellular response in detail.
In this study, we report the combination effects of doc-
etaxel (DOC) and doxorubicin (DOX), anticancer drugs
used widely in clinical applications, on the cell viability of
established human prostate cancer cell lines (PC3 and
DU145) at various drug concentrations and mixing ratios.
DOC is a semisynthetic taxane that inhibits the depolymer-
ization of the microtubules and results in G2/M phase cell
cycle arrest [13–16]. DOX is a member of the anthracyclines,
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which acts by intercalating with the DNA [17–19]. The latter
results in cell death attributed to DNA cleavage mediated by
topoisomerase II (TOP2) and is accompanied by G2/M phase
cell cycle arrest [20]. PC3 and DU145 are used as in vitro
models for the advanced hormone-refractory prostate cancer
(HRPC) [21–23].
HRPC has a low therapeutic response to conventional
chemotherapy [24–26]. DOC appeared to be the most potent
cytotoxic agent used today for the treatment of HRPC
[24, 27–29], yet the reported toxicity is still high. Extensive
optimization of DOC regimens has taken place to reduce
drug toxicity, yet the drug efficacy also became variable [30].
A number of clinical trials have shown that combination of
DOC and anthracyclines would benefit HRPC patients by
sensitizing cancer cells at lower DOC doses [13, 14, 31–36].
DOC has been concurrently used with other anticancer
drugs, such as prednisone, mitoxantrone, and estramustine
to treat prostate cancer [36–40]. Previous in vitro studies
showed that pretreatment with DOC rendered cancer cells
(BCap and OV2008) more sensitive to the DOC/DOX
combination [41]. Synergy between DOC and anthracyclines
was seen previously in in vitro studies [42–44]. DOC was
synergistic when combined with DOX or epirubicin at dose
levels equal to their IC50 values in PC3, DU145, and LnCap
cells [43]. Despite promising results in vitro, DOC-based
drug combinations need to be explored further.
The major advantage of combination therapy is avoiding
unnecessary toxicity through drug synergism. The combina-
tion effects of multiple drugs are frequently evaluated using
the unified theory [45, 46]. According to the theory, synergy
is concluded when the combined use of multiple drugs at
specific dose levels leads to therapeutic efficacy equivalent to
or greater than the sum of the antitumor effects achieved by
each drug individually at the same dose levels.
Although drug regimens are dependent on the dosing
schedule [47], this study is focused on either single-drug
treatments or multiple-drug treatments of DOC and DOX
at various mixing ratios. Four combination settings are
being tested by adjusting the ratios between DOC and DOX
(DOC/DOX) that range between 10−6∼108. Moreover, the
nature of the DOC/DOX combination is studied when the
drug concentrations are fixed for both of them at their half
maximal inhibitory concentrations (IC50). We expect that
the optimal mixing ratios determined in this study would be
used to propose not only a new therapeutic regimen, but also
promising drug combination delivery systems.
2. Materials and Methods
2.1. Materials. Docetaxel (DOC) and doxorubicin (DOX,
hydrochloride salt) were purchased from LC Laboratories
(Woburn, MA). Dimethyl sulfoxide (DMSO, molecular biol-
ogy grade,≥99.9%) and resazurin sodium salt were obtained
from Sigma Aldrich (St Louis, MO). Sodium hydroxide
(NaOH), sodium chloride (NaCl), and anhydrous sodium
phosphate dibasic (Na2HPO4) were from VWR (West
Chester, PA). Sodium phosphate monobasic dihydrate
(NaH2PO4·2H2O) was obtained from Fisher Scientific (Fair
Lawn, NJ). Phosphate-buffered saline (PBS, 0.1 M, pH 7.2,
0.9% NaCl) was prepared in house as a mixture of NaCl,
Na2HPO4, and NaH2PO4·2H2O. The pH was adjusted to 7.2
with 1 M NaOH.
2.2. Drug Formulations. DOC was dissolved in DMSO at
10 mg/mL (stock solution) and DOX stock solutions (10 mg/
mL) were prepared by dissolving the drug in sterile deionized
water (DI H2O). Stock solutions were stored in several
aliquots at−20◦C to avoid repetitive freeze-thaw cycles. DOC
and DOX stock solutions were serially diluted using DMSO
and DI H2O, respectively, to prepare drug working solutions.
Working solutions were diluted 100 times with cell-culture
media before treatment as described below.
2.3. Cell Lines. Human prostate cancer cell lines PC3 (pros-
tate grade IV adenocarcinoma, CRL-1435) and DU145
(prostate carcinoma, HTB-81) were obtained from the
American Type Culture Collection (ATCC, Manassas, VA).
PC3 and DU145 were cultured in F12K (ATCC, Manassas,
VA) and RPMI 1640 (Atlanta Biologicals, Lawrenceville, GA)
media, respectively. The cell culture media were supple-
mented with 10% fetal bovine serum (FBS) in the presence
of penicillin (100 U/mL) and streptomycin (100 µg/mL).
FBS, Penicillin, Streptomycin, and 0.25% trypsin/EDTA were
from Gibco-Invitrogen Corporation (Carlsbad, CA). Cells
were maintained in the logarithmic growth phase at 37◦C
in a humidified atmosphere containing 5% CO2 at all times.
Cells were tested routinely for mycoplasma contamination.
PC3 (5,000 cells/well) and DU145 (3,000 cells/well) were
seeded in 96-well plates and allowed to adhere overnight
prior to drug exposure. After preincubation, the cell culture
media were replaced with drug-containing media. The cells
were exposed to drugs for 72 hours, followed by cell viability
assessment for single and combination drug treatments as
described below.
2.4. Drug Treatment. We first determined the half maximal
inhibitory concentration (IC50) values of DOC and DOX
for each cell line. Drug concentrations ranged from 10−4 to
105 nM for the single-drug treatment. Multiple-drug treat-
ment effects were then evaluated in four combination
settings (Figure 1). Both DOC and DOX concentrations were
variable in Combination 1 and Combination 2. Combination
3 and Combination 4 were designed to investigate combina-
tion effects of one drug when the IC50 value of the other
drug remained fixed. In Combination 3, cells were treated
at the fixed IC50 of DOC in combination with variable DOX
concentrations. Cells in Combination 4 were exposed at the
fixed IC50 dose level of DOX as DOC concentrations were
variable. Combination effects of DOC and DOX were further
investigated at equipotent concentrations of the IC50 values
for each drug (7× 7 combination).
2.5. Cell Viability Assay. Cell viability was assessed using a
resazurin assay that indicates mitochondrial metabolic activ-
ity in live cells [48, 49]. Briefly, 10 µL of a 1 mM resazurin
solution in PBS was added to the vehicle- and drug-treated
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Figure 1: Drug combination settings used in this study. PC3 and DU145 cells were exposed to DOC and DOX at various concentrations and
mixing ratios for 72 hours. Dots on the lines denoted as Combination 1, 2, 3, and 4 indicate data points used to determine the combination
index and cytotoxicity values.
cells at the end of the treatment period. Cell viability was
determined three hours later by reading the fluorescence at
560 nm (Ex)/590 nm (Em). The fluorescence signals were
quantified using a Spectramax M5 plate reader (Molecular
Devices) equipped with a SoftMaxPro software.
2.6. Data Analysis. GraphPad Prism (version 5.02 for Win-
dows, GraphPad Software Inc., San Diego, USA) was
employed to produce dose-response curves by performing
nonlinear regression analysis. The viability of the treated cells
was normalized to the viability of the untreated (control)
cells, and cell viability fractions were plotted versus drug
concentrations in the logarithmic scale. IC50 values were
reported as mean values. The unified theory, introduced
byChou [45, 46], was used to evaluate the synergy, additivity
and antagonism of the DOC/DOX combination in PC3 and
DU145 cells. Combination index (CI) values were deter-
mined using the following equation:
CI = [DOC]
[DOC]x
+
[DOX]
[DOX]x
+
[DOC]× [DOX]
[DOC]x × [DOX]x
. (1)
We used the mutually nonexclusive model, based on the
assumption that drugs act through entirely different mecha-
nisms of action. [DOC] and [DOX] are drug concentrations
of DOC and DOX in combination, inhibiting x% of cell
viability. [DOC]x and [DOX]x are the doses of DOC and
DOX alone, respectively, inhibiting x% of cell viability. CI
values were used to determine synergy (CI < 0.9), additivity
(0.9 < CI < 1.1), and antagonism (CI > 1.1) of the drug
combinations tested.
Experiments were conducted in triplicate (n = 3) with 6
replications at each drug concentration level (r = 6).
3. Results
3.1. Single-Drug Treatment. IC50 values of DOC and DOX
alone were determined in PC3 and DU145 as summarized
in Table 1. DOC showed IC50 of 0.598 nM and 0.469 nM
for PC3 and DU145, respectively. Dose-response curves in
Figure 2, however, indicate that no complete cell death was
seen in either of the cell lines treated with DOC up to 103 nM
(Figures 2(a) and 2(c)). Cell viability decreased significantly
as DOC concentrations increased to 105 nM. Biphasic dose-
response curves revealed that the half effective dose (EC50)
values of DOC between the first and second phase were
significantly different (Table 1). Precise determination of the
EC50 values of DOC was unsuccessful in the second phase
(EC50 (2)) because we could not test concentrations higher
than 105 nM due to the precipitation of DOC in the cell
culture media. The IC50 values of DOX were estimated equal
to 908 nM and 343 nM for PC3 and DU145, respectively.
Although the IC50 values of DOX were higher than those
of DOC in both cell lines, DOX induced cell death in a
dose-dependent manner described by a monophasic dose-
response curve (Figures 2(b) and 2(d)). These results indicate
that the potency of each drug cannot be compared directly
simply by using the IC50 values. Therefore, we used DOC at
a dose level equal to the EC50 (1) value when combined with
DOX. Overall cytotoxicity trends show that DU145 is more
sensitive to DOC and DOX single-drug treatments than PC3.
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Figure 2: Dose response curves. PC3 and DU145 cells were exposed to either DOC (a) and (c) or DOX (b) and (d) for 72 hours, followed
by the resazurin assay to determine cell viability (mean ± SD, n = 6).
Table 1: Cytotoxicity of docetaxel (DOC) and doxorubicin (DOX) in hormone-refractory PC3 and DU145 cancer cell linesa. IC50 values
are given as mean.
PC3 DU145
IC50b EC50 (1)c EC50 (2)c IC50b EC50 (1)c EC50 (2)c
DOC (nM) 0.598 0.500d 92,000d 0.469 0.392 104,000d
DOX (nM) 908 N.D. N.D. 343 N.D. N.D.
a
Cells were treated with either DOC or DOX alone.
bIC50 denotes the half maximal inhibitory concentration.
cEC50 (1) and EC50 (2) indicate the half effective concentrations in the first (1) and second (2) phase of the biphasic curve used to fit the cell viability data.
dApproximate estimation due to insufficient data points.
N.D: Not determined.
3.2. Synergy of Multiple Drug Combinations. Figure 3 shows
the synergy maps of the DOC and DOX combination, and
Figure 4 represents the cytotoxicity of the drug combinations
for PC3 and DU145.
Drug synergy and significant cell death (∼60%) was
seen in PC3 at 104 nM DOC and 103 nM DOX. However,
the DOC concentration was too high to take advantage of
the drug combination in terms of achieving our goal of
obtaining the desirable therapeutic effect by administering
low doses of the drugs in combination. We observed
moderate cytotoxicity on the PC3 (49∼58% cell death) at the
concentration levels of DOC and DOX equal to their IC50
values. Moreover, drug synergy was observed when PC3 cells
were treated with low doses of DOC in combination with
DOX doses approximating its IC50 values. Drug synergy was
accompanied by effective cell death (>50%) at DOC levels
varying from 0.01 to 10 nM, while the DOX dose was equal
to its IC50 value.
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Figure 3: Synergy maps compiling combination index (CI) values. The dots in the figure indicate antagonism (CI > 1.1, red), additivity
(0.9 < CI < 1.1, yellow), and synergism (CI < 0.9, green) between DOC and DOX against PC3 and DU145 cells at combination settings
shown in Figure 1. Experiments were performed in triplicate.
DOC/DOX combinations in DU145 appeared additive or
antagonistic in most combination settings (Figure 3). How-
ever, synergy was observed in the DU145 at the highly limited
concentration range of 0.5 nM DOC plus DOX between 1–
50 nM. Cell death reported on the DU145 was 11∼33%
for the synergistic combinations (Figure 4). Interestingly,
significant cell death was noted when doses of DOC ranging
from 1 to 104 nM combined with 343 nM of DOX (>80%)
(Figure 4). Nevertheless, all those mixing ratios proved to be
antagonistic (Figure 3).
These results demonstrated that the DOC/DOX combi-
nation was synergistic in PC3, while synergy was seen in
limited concentration levels in the DU145.
3.3. Synergy of the 7 × 7 Combination. We further inves-
tigated DOC/DOX combination effects by exposing the
prostate cancer cells to DOC/DOX mixing ratios at seven
dose levels (7×7 combination) (Figures 5 and 6). These drug
concentrations were selected based on predetermined IC50
values for each drug (data not shown). Figure 5 shows the
synergy maps, indicating that the DOC/DOX combination
effects can be controlled by simply changing the mixing
ratios of two drugs at their IC50 values. PC3 were sensitive
to the combination of low doses of DOC varying from 0.125
to 0.5 nM (25∼100% of DOC IC50) with 2,000∼8,000 nM
DOX (2∼8 fold of DOX IC50). In DU145, the DOC/DOX
combination showed strong synergy only when 0.125 or
0.25 nM DOC was combined with 1,372 nM DOX (4-fold
DOX IC50) (Figure 5). Although DOX appeared to make
prostate cancer cells more susceptible to DOC, by decreasing
the DOC doses necessary for cell death, the observed cell
death never exceeded 80% in either of the cell lines used.
Data collected regarding the combination index values and
the cytotoxicity presented on Figures 5 and 6, respectively,
also suggests that in the DU145 cell line, the DOC/DOX
combination might have a narrow mixing ratio window for
exerting its antitumor activity effectively.
4. Discussion
4.1. DOC/DOX Combination in Prostate Cancer In Vitro
Models. Prostate cancers that no longer respond to hormone
therapy are categorized as hormone-refractory and are typ-
ically accompanied by metastatic lesions. DOC is one of the
most potent anticancer drugs for HRPC treatment [27, 28],
yet its clinical applications are limited due to low bioavail-
ability and high toxicity. DOX is widely used clinically for
the treatment of various cancers and has been used in
the past in prostate cancer patients [31, 50–53]. In this
study, we investigated the cytotoxic effect of the DOC/DOX
combination on metastatic prostate cancer cells derived from
the bone (PC3) and brain (DU145).
A number of studies [43, 47], including our own, have
shown that DOX causes dose-dependent cytotoxicity in
6 Biochemistry Research International
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Figure 4: Drug combination cytotoxicity. The grayscale dots in the figure show average percent cell death of PC3 and DU145 cells at each
combination setting from triplicate experiments shown in Figure 3.
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Figure 5: Focused synergy maps compiling combination index (CI) values. The CI values were determined with a narrower dose area with
7 × 7 drug combination design. Drug antagonism (red), additivity (yellow), and synergism (green) were determined for PC3 and DU145
cells exposed to DOC and DOX for 72 hours.
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Figure 6: Focused drug combination cytotoxicity. The grayscale dots in the figure demonstrate percent cell death of PC3 and DU145 with
7× 7 DOC/DOX combination settings.
cancer cells. We also confirmed that the cytotoxic profile of
DOX is a monophasic one on both cancer cell lines. In respect
to DOC, our data are in agreement with previous findings
that showed biphasic cellular response of breast cancer cell
lines to DOC [54]. At low dose levels, DOC is known to cause
nonapoptotic cell death, which is accompanied by senes-
cence, necrosis, and mitotic catastrophe [54–57]. Mitotic
catastrophe is cell death occurring during metaphase and
distinct from apoptosis-related cell death observed at DOC
concentrations at the micromolar range. Therefore, we
hypothesize that the initial decrease on the observed cell
viability (EC50 (1)) is due to mitotic catastrophe, while
apoptosis is the cause for the cell death observed at DOC
concentrations higher than 10 µM (Figure 2). Interestingly,
pharmacokinetic studies have shown that the recommended
administration schedule of DOC results in drug blood levels
in the micromolar range [58, 59]. Therefore, it is safe to
attribute the observed antitumor activity of DOC in the
clinic to DOC-induced cell apoptosis.
DOC and DOX cause cytotoxic effects through com-
pletely different mechanisms of action. DOC and other
taxanes act by binding to microtubules and change the for-
mation of the cell cytoskeleton and cell signaling [15]. Fur-
thermore, DOC treatment leads to phosphorylation of the
antiapoptotic protein Bcl2 [16], preventing the protein from
dimerizing with its proapoptotic partner Bax. The readily
available Bax forms homodimers instead and induces apop-
tosis. Topoisomerase II inhibitors, including DOX, primarily
induce cell death through DNA damage [17, 19]. They are
also known to induce free-radical DNA injury and lipid
peroxidation [60, 61]. Additionally, the interaction between
anthracyclines and the cytoskeleton has been studied [62].
DOX is known to delay G-actin polymerization and prevents
the elongation of small actin filaments performed during
the polymerization in vitro [63]. Therefore, cells in dynamic
movement or mitosis could be more susceptible to DOX
treatment. G-actin rearrangement failed in breast cancer cells
treated with cytochalasin B, a microtubule inhibitor, being in
combination with DOX [64]. These results suggest that the
mechanisms of action of DOC and DOX are not distinctively
independent and that actin could be a potential target that
can be inhibited cooperatively by DOC and DOX in drug
combinations tested in this study.
4.2. Clinical Impact of the Multiple Drug Combination. The
antitumor activity of a cytotoxic agent depends on the drug
levels at the tumor site. The presence of the anticancer agent
at an optimal concentration is essential for interaction with
its target and for inducing a pharmacodynamic effect. More-
over, intracellular metabolism, interaction with transporters,
and interactions with concomitantly given anticancer agents
may have an impact on the pharmacokinetic profile of a
cytotoxic agent. For these reasons, we investigated the cellular
response of PC3 and DU145 to the DOC/DOX combination
by varying the concentrations and mixing ratios of the
drugs (Figure 1). In Figure 3, we calculated the combination
index (CI) values of DOC/DOX combination and deter-
mined synergism, additivity, and antagonism. The effect of
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the DOC/DOX combination on the cell viability is presented
on Figure 4. The information collected by both the synergy
maps and the DOC/DOX-induced cell death for the various
drug mixing ratios provided us with a more thorough under-
standing of the potential in vivo cytotoxic effect of the afore-
mentioned drug combination. It was revealed that cell death
at high drug concentrations was not always attributed to
effective drug combinations. In most cases, drug antagonism
was observed at dose levels greater than the IC50 values
of each drug. In PC3, strong drug synergism and effective
cell death (>50%) were seen in concentration ranges close
to the IC50 value of each of the drugs. Interestingly, the
DU145 cell line was more sensitive to DOC or DOX alone
but showed greater cell survival when the two drugs were
combined. Further studies are necessary to elucidate the
cellular mechanisms behind the limited cellular response of
DU145 when treated with the DOC/DOX combination.
4.3. Clinical Significance of the Synergy Observed with the
7 × 7 Combination. The DOC/DOX combination was pre-
viously tested in breast cancer in vitro models, using 5 nM
DOC and 100 nM DOX [41]. In our study, the nature of
the DOC/DOX combination was assessed in more detail
at various mixing ratios of DOC and DOX concentrations
equal to their IC50 values. Synergy was seen in a broad drug
concentration range in PC3, while only limited combination
settings induced synergistic effects in DU145 (Figure 5). Fig-
ure 6 indicates that cell death of potential clinical significance
was observed at dose levels greater than the IC50 values for
DOX. This finding is more pronounced in the PC3 cell line.
We found that DOC can be potent in prostate cancer at
nanomolar concentrations by using DOX as a combination
counterpart, although the anthracycline is 1000 times less
toxic than DOC. We were able to identify fewer cases of
synergy in the DU145 than in the PC3 cell line. We observed
strong synergy at DOC dose levels lower than its IC50
value plus DOX at dose levels 2–4-fold higher than its IC50
in both PC3 and DU145, suggesting that the significantly
low DOC concentrations would be sufficient to trigger the
synergistic effects of the drug combination. These results are
important because concentrations equal to the IC50 values
for each cytotoxic agent can be achieved in the clinical
setting [58, 59, 65, 66]. However, the efficacy of the drug
combination represented as cell death remained lower than
75%, indicating that DOC/DOX combinations are moder-
ately cytotoxic. To conclude, even though complete cell death
was not seen in our studies, the DOC/DOX combination
could potentially benefit prostate cancer patients by reducing
the DOC-mediated toxicity. We expect that the therapeutic
efficacy of the proposed DOC/DOX combination will be
enhanced by further optimization of the regimen.
5. Conclusions
In this study, we identified optimal combination settings
for DOC and DOX, anticancer drugs commonly used in
clinical applications, in hormone-refractory prostate cancer
cells (PC3 and DU145). Strong drug synergy was seen at dose
levels lower than the IC50 values of DOC in combination
with 2∼4-fold IC50 values of DOX. In comparison to existing
cytotoxicity assays that evaluate drug potency simply by
using IC50 values, the synergy maps allowed facile and rea-
sonable evaluation of the drug combination effect, irrespec-
tive of the monophasic or biphasic cytotoxicity patterns of
drugs used in combination. By combining information that
includes the combination index values and the cytotoxicity
observed, we were able to identify drug ratios of DOC and
DOX that could be potentially worth testing in future in vivo
studies. We also found that drug synergy was not always cor-
related with cell death when a drug with high potency (DOC)
was used at dose levels higher than its IC50 in combination
with a less potent drug (DOX). Our study demonstrated
optimal concentration ratios of DOC and DOX in combi-
nation for the treatment of PC3 and DU145, which could
improve chemotherapy for prostate cancer patients and can
be used for the design of a multiple-drug delivery system
in the future. In conclusion, the combination of DOC with
DOX evaluated in this study potentiates the cytotoxic proper-
ties of DOC given at significantly reduced doses compared to
the clinically relevant ones, and thus could potentially protect
cancer patients from unnecessary DOC-related toxicity.
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